It promotes fat breakdown and utilization
Its side effect profile includes depression, suicidal thoughts, fatigue, and insomnia (Zerilli 2015
Pei T, Liu C, Liu T, Xiao L, Luo B, Tan J, Li X, Zhou G, Duan C, Huang W (2018) miR-194-3p represses the progesterone receptor and decidualization in eutopic endometrium from women with endometriosis
like all therapies, GLP-1s can cause side effects including nausea, vomiting and other gastrointestinal issues
All drugs show improvement during maintenance dosing: CT-388 nausea dropped from 83% (titration) to 54% (maintenance) Semaglutide and tirzepatide GI events are described as "transient" and occurring "primarily during dose escalation" Slower titration schedules generally reduce GI severity This is clinically relevant: patients who tolerate the first 4-8 weeks of dose escalation will likely experience manageable side effects long-term